{"id":37655,"date":"2025-07-21T15:48:26","date_gmt":"2025-07-21T07:48:26","guid":{"rendered":"https:\/\/flcube.com\/?p=37655"},"modified":"2025-07-21T15:48:26","modified_gmt":"2025-07-21T07:48:26","slug":"wuxi-biologics-passes-fda-pre-approval-inspection-with-zero-critical-findings","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37655","title":{"rendered":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings"},"content":{"rendered":"\n

WuXi Biologics (HKG: 2269<\/a>) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company’s commitment to global regulatory standards and quality excellence.<\/p>\n\n\n\n

Inspection Details<\/strong>
The nine-day FDA inspection comprehensively covered WuXi Biologics’ quality management system and the full production processes of two drug substance plants (MFG1 and MFG5) and three drug product plants (DP1, DP2, and DP5) in Wuxi, China. Notably, DP5, the company\u2019s first commercial pre-filled syringe (PFS) filling plant, successfully passed a regulatory inspection for the first time. This milestone highlights WuXi Biologics’ expanding capabilities in advanced drug delivery systems.<\/p>\n\n\n\n

Global Compliance Milestones<\/strong>
As of the end of 2024, WuXi Biologics had successfully passed 42 global regulatory inspections and secured 97 manufacturing licenses from regulatory authorities across the U.S., Europe, China, Singapore, Japan, and Canada. These achievements for its 16 global manufacturing sites reflect the company’s robust compliance and quality assurance framework, reinforcing its position as a trusted partner in the global biologics manufacturing landscape.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities…<\/p>\n","protected":false},"author":1,"featured_media":37656,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[19,952,292],"class_list":["post-37655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cro-cmo-cdmo","tag-hkg-2269","tag-wuxi-biologics"],"yoast_head":"\nWuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37655\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings\" \/>\n<meta property=\"og:description\" content=\"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37655\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-21T07:48:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings\",\"datePublished\":\"2025-07-21T07:48:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2109.webp\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 2269\",\"WuXi Biologics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37655#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37655\",\"name\":\"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2109.webp\",\"datePublished\":\"2025-07-21T07:48:26+00:00\",\"description\":\"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37655\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2109.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2109.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37655#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings - Insight, China's Pharmaceutical Industry","description":"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37655","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings","og_description":"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.","og_url":"https:\/\/flcube.com\/?p=37655","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-21T07:48:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37655#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37655"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings","datePublished":"2025-07-21T07:48:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37655"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37655#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","keywords":["CRO \/ CMO \/ CDMO","HKG: 2269","WuXi Biologics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37655#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37655","url":"https:\/\/flcube.com\/?p=37655","name":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37655#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37655#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","datePublished":"2025-07-21T07:48:26+00:00","description":"WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities successfully passed the U.S. Food and Drug Administration\u2019s (FDA) pre-approval licensing inspection (PLI) without any critical findings or data integrity issues. This achievement underscores the company's commitment to global regulatory standards and quality excellence.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37655#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37655"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37655#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","width":1080,"height":608,"caption":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37655#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2109.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37655"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37655\/revisions"}],"predecessor-version":[{"id":37657,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37655\/revisions\/37657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37656"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}